ArticleHealth economics review2019

The cost-effectiveness of pegaspargase versus native asparaginase for first-line treatment of acute lymphoblastic leukaemia: a UK-based cost-utility analysis.

Xingdi Hu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.